A Heart Drug Discovery Hiding in Plain Sight: Semaglutide Cut Major Cardiovascular Events by 20%
In adults with overweight or obesity and established cardiovascular disease without diabetes, semaglutide reduced major adverse cardiovascular events by 20%. Researchers continue to investigate the exact biological mechanisms behind the outcome.
Source: News-Medical.Net
Read the original story →